Breaking News Instant updates and real-time market news.

After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.

Leerink analyst Geoffrey Porges lowered his price target for Regeneron to $511 from $530, citing cautious guidance following the company's Q2 results. Nonetheless, the analyst points out its Eylea "solid" sales, beating by 2% in the U.S. and 5% overall. The analyst remains positive about Regeneron's product portfolio, strategy, management, and long-term potential. He reiterates an Outperform rating on the shares.

08/05/16

BARD

08/05/16DOWNGRADETarget $448BARDNeutral

Regeneron downgraded to Neutral at Baird

As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.

09/21/16

RBCM

09/21/16NO CHANGERBCM

Regeneron Fasinumab deal positive, says RBC Capital

After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.

09/21/16

ROTH

09/21/16NO CHANGETarget $520ROTHBuy

Teva deal important for Regeneron, says at Roth Capital

Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.

SNYSanofi

$38.19

0.36 (0.95%)

09/08/16

09/08/16UPGRADE

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Overweight from Neutral at JPMorgan with analyst Chris Schott saying new products could drive upside to 2017 estimates while the risk/reward is favorable into solanezumab data late this year. 2. Johnson Controls (JCI) upgraded to Outperform from Neutral at Macquarie with analyst Mike Wood saying he has increased confidence on the commercial recovery, upside to Tyco synergies, improving cash flow, and potential for further portfolio simplification. 3. Sanofi (SNY) upgraded to Buy from Hold at Berenberg. 4. VMware (VMW) reinstated with Overweight from Neutral at JPMorgan with analyst Mark Murphy saying partner interviews highlight strength in the company's products and Dell has publicly stated that its global distribution network can lead to $1B of incremental VMware revenue. 5. Volaris (VLRS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

09/09/16

LEER

09/09/16NO CHANGELEER

Leerink updates therapeutics best ideas for 2016

In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chesapeake Utilities (CPK) initiated with a Neutral at Ladenburg. 2. CONSOL (CNX) initiated with a Neutral at Goldman. 3. Johnson Controls (JCI) assumed with an Equal Weight at Barclays. 4. American Midstream Partners (AMID) initiated with a Buy at Janney Capital. 5. Brookfield Infrastructure (BIP) coverage resumed with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Abercrombie & Fitch (ANF) downgraded to Sell from Hold at Argus with analysts John Eade and Katelyn Bayone citing the company's third quarter miss and what they see as its "challenging sales outlook for the remainder of the year." 2. Duluth Holdings (DLTH) downgraded to Hold from Buy at Stifel and to Market Perform from Outperform at William Blair. 3. DAVIDsTEA (DTEA) downgraded to Market Perform from Outperform at BMO Capital and to Market Perform from Outperform at William Blair. 4. Hilton (HLT) downgraded to Outperform from Buy at CLSA with analyst Jon Oh citing valuation. 5. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying the recent weakness in shares provides an "excellent entry point" ahead of several critical pipeline events that have the potential "to transform this giant into an exciting growth story." 2. Autodesk (ADSK) upgraded to Buy from Hold at Canaccord with analyst Richard Davis citing expectations for improved free cash flow, as he sees a path to $6 in FCF by 2020 and $11 per share in 2022. 3. Eaton (ENT) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying optionality of the company's balance sheet should offset broad weakness across its end markets. 4. Fluor (FLR) upgraded to Buy from Neutral at Citi with analyst Andrew Kaplowitz saying the company is positioned to outperform given amid oil and gas capex stabilization, a lift off the bottom in mining off the bottom and "muted" 2017 expectations. 5. Sysco (SYY) upgraded to Neutral from Sell at Goldman. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.